Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

ers us greater flexibility to accelerate these programs," concluded Mr. Milinazzo.

Operational Overview On October 29, 2013, the Company announced the 12-month follow up results from the MASTER trial for its MGuard Embolic Protection Stent (EPS).The findings showed that the novel MGuard EPS provides a significant acute advantage in reducing ST segment elevation versus traditional bare metal and drug eluting stents. As a result, MGuard may hold the potential to prolong the survival of heart attack victims, as evidenced by the 12-month data.  The 12-month follow up results are an important data point for physicians evaluating the MGuard, as the first year is an important period for evaluating a patient who has received a stent during a heart attack.  As the Company now has this data in hand, it intends to ramp commercial activity for the remainder of 2013 and 2014.

The Company continues enrollment in its MASTER II clinical trial to evaluate the safety and effectiveness of the MGuard™ Prime EPS in patients suffering from ST Elevation Myocardial Infarction (STEMI). In total, the multi-center, randomized trial is expected to include up to 70 sites in the U.S. and Europe and as many as 1,114 patients. The results are intended to support the Company's Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) to market the MGuard™ Prime MicroNet™ covered coronary stent system in the U.S.

While the MASTER II trial is fully funded, the Company took additional steps to secure strategic financing and protect shareholder value.  On October 24th, the Company announced it had secured $10 million in venture debt to support expanding its emerging clinical research and product development efforts.  The Company also put into place a one year stockholder rights plan which the Board believed was prudent in order to protect shareholders' interests. 

Quarter Ended S
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
(Date:8/27/2015)... ALEXANDRIA, Va. , Aug. 27, 2015 /PRNewswire-USNewswire/ ... in the Food and Drug Administration,s (FDA,s) draft ... including reference products and biosimilars, to bear a ... years, AMCP has been seeking a decision from ... joined 18 diverse health care stakeholders urging the ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... and WILMINGTON, Del., Dec. 21 Eli Lilly and ... (Nasdaq: INCY ) announced today that they have ... for the development and commercialization of Incyte,s oral JAK1/JAK2 ... and autoimmune diseases. The lead compound, INCB28050, is currently ...
... , CARLSBAD, Calif., Dec. 21 Isis ... will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. ... license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). ... and OncoGenex that has completed a successful Phase 2 program ...
Cached Medicine Technology:Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 2Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 3Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 4Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 5Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies 6Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3
(Date:8/30/2015)... ... August 31, 2015 , ... Intellitec Solutions, ... Convention & Expo October 5th & 6th in San Antonio, TX. Dedicated to ... brings industry professionals from all over the country come to share the latest ...
(Date:8/30/2015)... ... , ... Lizzie’s Lice Pickers , a company that offers professional live ... offering lice head checks for just $10, which is a significant discount from the ... their lice treatment products. “With kids returning to school, it is very important to ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( ... expansion of global cosmeceutical and skin care brands. Mr. Fernandez comes with ... 25 years working in operations, purchasing and management for some of the nations ...
(Date:8/29/2015)... VA (PRWEB) , ... August 30, 2015 , ... ... Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent ... more than a simple digital handwritten signature. , Clinical trial sites ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Dr. Tim Novelli, ... His mission is to increase acceptance of the chiropractic field in the military. ... further debilitate them. Although Chiropractic was made available to the VA program over ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... parents worry babies get ,too much too soon, but ... May 24 (HealthDay News) -- Some American parents are ... they,re worried that their infants are getting too many ... issues. , The issue has been especially persistent when ...
... ... project management support and peer-to-peer learning opportunities to aid in transformation process, ... Leawood, ... Physicians, today announced a new service offering aimed at helping small primary care ...
... Knowledge regarding environmental factors influencing the risk of ... this area. In particular, the roles of smoking and ... this month in the Journal of Alzheimer,s Disease ... the risk of Alzheimer,s disease, particularly in women who ...
... ... new facility , ... (Vocus) May 24, 2010 -- AthletiCo Physical and Occupational Therapy announces the relocation ... The new facility is located in the Hillcrest Center across the street from the Worden ...
... ... ... InPro Corporation announced it has joined the American Academy of Healthcare Interior Designers (AAHID) ... certifies the knowledge, skills and abilities of healthcare interior designers. Board Certified Healthcare Interior ...
... ... its expansion into new office space in the Century Square building in downtown Seattle, Washington. ... Vancouver, B.C., supports a number of employees on the East Coast and in the Midwest ... ...
Cached Medicine News:Health News:No Benefit Seen in Delaying Infant Vaccinations 2Health News:No Benefit Seen in Delaying Infant Vaccinations 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 2Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 4Health News:AthletiCo's Champaign-Urbana Physical Therapy Center Relocates to 2040 S. Neil in Champaign 2Health News:AthletiCo's Champaign-Urbana Physical Therapy Center Relocates to 2040 S. Neil in Champaign 3Health News:InPro Becomes AAHID Industry Partner 2Health News:Quorum Review IRB Commemorates New Office with Ribbon Cutting Ceremony 2
... 64 is the ultimate CT solution ... Our system fuses the latest and ... applications delivering unprecedented image quality. It ... to meet the requirements for cardiac ...
... MONO-plus test uses direct ... the qualitative detection of ... whole blood, serum or ... waived whole blood kit ...
One inch disposable patch electrode uses a specially formulated adhesive solid gel. Reusable lead wire with snap connector provides economic benefits. Ideal for sleep studies where leg movement or EK...
... Made with elastic fabric, these head cap ... need to begin testing. Each Electro-Cap System ... the International 10-20 System. When you place ... are using with your head cap system ...
Medicine Products: